Switch theme
Sign up to access all valuation multiples
Yuhan Corp is a pharmaceutical company. The core business of the company is classified as primary and specialty care, dietary supplements, household and animal care, and contract manufacturing of active pharmaceutical ingredients. The company offers one-stop custom synthesis services from research and development to commercial production of active pharmaceutical products (APIs) and intermediates for the following disease treatments: antivirals (HCV and HIV), antibiotics, antihistamines, antidiabetics, beta-lactamase inhibitors, CNS intermediates, and PEGylated compounds for international markets.
1926
n/a
LTM Revenue $1.5B
LTM EBITDA $101M
$5.7B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Yuhan has a last 12-month revenue (LTM) of $1.5B and a last 12-month EBITDA of $101M.
In the most recent fiscal year, Yuhan achieved revenue of $1.5B and an EBITDA of $101M.
Yuhan expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Yuhan valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.5B | XXX | $1.5B | XXX | XXX | XXX |
| Gross Profit | $508M | XXX | $501M | XXX | XXX | XXX |
| Gross Margin | 33% | XXX | 33% | XXX | XXX | XXX |
| EBITDA | $101M | XXX | $101M | XXX | XXX | XXX |
| EBITDA Margin | 6% | XXX | 7% | XXX | XXX | XXX |
| EBIT | $55.1M | XXX | $39.9M | XXX | XXX | XXX |
| EBIT Margin | 4% | XXX | 3% | XXX | XXX | XXX |
| Net Profit | $58.4M | XXX | $51.4M | XXX | XXX | XXX |
| Net Margin | 4% | XXX | 3% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Yuhan's stock price is KRW 104217 (or $76).
Yuhan has current market cap of KRW 7.81T (or $5.7B), and EV of KRW 7.81T (or $5.7B).
See Yuhan trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $5.7B | $5.7B | XXX | XXX | XXX | XXX | $0.74 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Yuhan has market cap of $5.7B and EV of $5.7B.
Yuhan's trades at 3.8x EV/Revenue multiple, and 56.1x EV/EBITDA.
Equity research analysts estimate Yuhan's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Yuhan has a P/E ratio of 97.3x.
See valuation multiples for Yuhan and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $5.7B | XXX | $5.7B | XXX | XXX | XXX |
| EV (current) | $5.7B | XXX | $5.7B | XXX | XXX | XXX |
| EV/Revenue | 3.7x | XXX | 3.8x | XXX | XXX | XXX |
| EV/EBITDA | 56.5x | XXX | 56.1x | XXX | XXX | XXX |
| EV/EBIT | 103.0x | XXX | 142.4x | XXX | XXX | XXX |
| EV/Gross Profit | 11.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | 97.3x | XXX | 110.5x | XXX | XXX | XXX |
| EV/FCF | -1591.3x | XXX | -98.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialYuhan's last 12 month revenue growth is 9%
Yuhan's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Yuhan's rule of 40 is 19% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Yuhan's rule of X is 29% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Yuhan and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 9% | XXX | 9% | XXX | XXX | XXX |
| EBITDA Margin | 6% | XXX | 7% | XXX | XXX | XXX |
| EBITDA Growth | 44% | XXX | -4% | XXX | XXX | XXX |
| Rule of 40 | 19% | XXX | 16% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 29% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 8% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 11% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 31% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Yuhan acquired XXX companies to date.
Last acquisition by Yuhan was XXXXXXXX, XXXXX XXXXX XXXXXX . Yuhan acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Yuhan founded? | Yuhan was founded in 1926. |
| Where is Yuhan headquartered? | Yuhan is headquartered in South Korea. |
| Who is the CEO of Yuhan? | Yuhan's CEO is Mr. Wook-je Cho. |
| Is Yuhan publicy listed? | Yes, Yuhan is a public company listed on KRX. |
| What is the stock symbol of Yuhan? | Yuhan trades under 000100 ticker. |
| When did Yuhan go public? | Yuhan went public in 1962. |
| Who are competitors of Yuhan? | Similar companies to Yuhan include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Yuhan? | Yuhan's current market cap is $5.7B |
| What is the current revenue of Yuhan? | Yuhan's last 12 months revenue is $1.5B. |
| What is the current revenue growth of Yuhan? | Yuhan revenue growth (NTM/LTM) is 9%. |
| What is the current EV/Revenue multiple of Yuhan? | Current revenue multiple of Yuhan is 3.7x. |
| Is Yuhan profitable? | Yes, Yuhan is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Yuhan? | Yuhan's last 12 months EBITDA is $101M. |
| What is Yuhan's EBITDA margin? | Yuhan's last 12 months EBITDA margin is 6%. |
| What is the current EV/EBITDA multiple of Yuhan? | Current EBITDA multiple of Yuhan is 56.5x. |
| What is the current FCF of Yuhan? | Yuhan's last 12 months FCF is -$3.6M. |
| What is Yuhan's FCF margin? | Yuhan's last 12 months FCF margin is 0%. |
| What is the current EV/FCF multiple of Yuhan? | Current FCF multiple of Yuhan is -1591.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
